TITO R MENDOZA to Cross-Over Studies
This is a "connection" page, showing publications TITO R MENDOZA has written about Cross-Over Studies.
Connection Strength
0.057
-
Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes. 2016 Feb 19; 14:24.
Score: 0.031
-
A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J. 2014 Jan-Feb; 20(1):8-14.
Score: 0.026